166 related articles for article (PubMed ID: 27112325)
21. AKT1 gene mutation levels are correlated with the type of dermatologic lesions in patients with Proteus syndrome.
Lindhurst MJ; Wang JA; Bloomhardt HM; Witkowski AM; Singh LN; Bick DP; Gambello MJ; Powell CM; Lee CR; Darling TN; Biesecker LG
J Invest Dermatol; 2014 Feb; 134(2):543-546. PubMed ID: 23884311
[No Abstract] [Full Text] [Related]
22. Heterozygous somatic activating AKT1 mutation in a case of Proteus syndrome with mental retardation.
Yang Z; Xu Z; Sun YJ; Ma L
J Dermatol; 2014 Feb; 41(2):188-9. PubMed ID: 24387135
[No Abstract] [Full Text] [Related]
23. Molecular Diagnosis of Mosaic Overgrowth Syndromes Using a Custom-Designed Next-Generation Sequencing Panel.
Chang F; Liu L; Fang E; Zhang G; Chen T; Cao K; Li Y; Li MM
J Mol Diagn; 2017 Jul; 19(4):613-624. PubMed ID: 28502725
[TBL] [Abstract][Full Text] [Related]
24. Thrombosis risk factors in PIK3CA-related overgrowth spectrum and Proteus syndrome.
Keppler-Noreuil KM; Lozier J; Oden N; Taneja A; Burton-Akright J; Sapp JC; Biesecker LG
Am J Med Genet C Semin Med Genet; 2019 Dec; 181(4):571-581. PubMed ID: 31490637
[TBL] [Abstract][Full Text] [Related]
25. A dyadic genotype-phenotype approach to diagnostic criteria for Proteus syndrome.
Sapp JC; Buser A; Burton-Akright J; Keppler-Noreuil KM; Biesecker LG
Am J Med Genet C Semin Med Genet; 2019 Dec; 181(4):565-570. PubMed ID: 31692258
[TBL] [Abstract][Full Text] [Related]
26. Hypertrichotic patches as a mosaic manifestation of Proteus syndrome.
Pithadia DJ; Roman JW; Sapp JC; Biesecker LG; Darling TN
J Am Acad Dermatol; 2021 Feb; 84(2):415-424. PubMed ID: 32035943
[TBL] [Abstract][Full Text] [Related]
27. High-level somatic mosaicism of AKT1 c.49G>A mutation in skin scrapings from epidermal nevi enables non-invasive molecular diagnosis in patients with Proteus syndrome.
Wieland I; Tinschert S; Zenker M
Am J Med Genet A; 2013 Apr; 161A(4):889-91. PubMed ID: 23436452
[No Abstract] [Full Text] [Related]
28. Prenatal diagnosis of a fetus with Proteus syndrome.
Fogarty L; Currie L; Skidmore D; Oviedo A; Sinha N; Coolen J
Prenat Diagn; 2018 May; 38(6):467-470. PubMed ID: 29574940
[No Abstract] [Full Text] [Related]
29. Repression of AKT signaling by ARQ 092 in cells and tissues from patients with Proteus syndrome.
Lindhurst MJ; Yourick MR; Yu Y; Savage RE; Ferrari D; Biesecker LG
Sci Rep; 2015 Dec; 5():17162. PubMed ID: 26657992
[TBL] [Abstract][Full Text] [Related]
30. Extending the spectrum of AKT1 mosaicism: not just the Proteus syndrome.
Polubothu S; Al-Olabi L; Wilson L; Chong WK; Kinsler VA
Br J Dermatol; 2016 Sep; 175(3):612-4. PubMed ID: 26872686
[No Abstract] [Full Text] [Related]
31. Mutant AKT1 in Proteus syndrome.
Marsh DJ; Trahair TN; Kirk EP
N Engl J Med; 2011 Dec; 365(22):2141-2; author reply 2142. PubMed ID: 22129268
[No Abstract] [Full Text] [Related]
32. Myocardial fat overgrowth in Proteus syndrome.
Hannoush H; Sachdev V; Brofferio A; Arai AE; LaRocca G; Sapp J; Sidenko S; Brenneman C; Biesecker LG; Keppler-Noreuil KM
Am J Med Genet A; 2015 Jan; 167A(1):103-10. PubMed ID: 25377688
[TBL] [Abstract][Full Text] [Related]
33. Pulmonary manifestations and management of proteus syndrome.
Li CY; Chang YL; Chen WC; Lee YC
J Formos Med Assoc; 2010 May; 109(5):397-400. PubMed ID: 20497874
[TBL] [Abstract][Full Text] [Related]
34. Characterization of the hepatosplenic and portal venous findings in patients with Proteus syndrome.
Takyar V; Khattar D; Ling A; Patel R; Sapp JC; Kim SA; Auh S; Biesecker LG; Keppler-Noreuil KM; Heller T
Am J Med Genet A; 2018 Dec; 176(12):2677-2684. PubMed ID: 30346092
[TBL] [Abstract][Full Text] [Related]
35. Clinical Phenotype and Bone Biopsy Characteristics in a Child with Proteus Syndrome.
Al Kaissi A; Misof BM; Laccone F; Blouin S; Roschger P; Kircher SG; Shboul M; Mindler GT; Girsch W; Ganger R
Calcif Tissue Int; 2021 Nov; 109(5):586-595. PubMed ID: 34003338
[TBL] [Abstract][Full Text] [Related]
36. Mutation analysis of the tumor suppressor PTEN and the glypican 3 (GPC3) gene in patients diagnosed with Proteus syndrome.
Thiffault I; Schwartz CE; Der Kaloustian V; Foulkes WD
Am J Med Genet A; 2004 Oct; 130A(2):123-7. PubMed ID: 15372512
[TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamic Study of Miransertib in Individuals with Proteus Syndrome.
Keppler-Noreuil KM; Sapp JC; Lindhurst MJ; Darling TN; Burton-Akright J; Bagheri M; Dombi E; Gruber A; Jarosinski PF; Martin S; Nathan N; Paul SM; Savage RE; Wolters PL; Schwartz B; Widemann BC; Biesecker LG
Am J Hum Genet; 2019 Mar; 104(3):484-491. PubMed ID: 30803705
[TBL] [Abstract][Full Text] [Related]
38. Molecular heterogeneity of the cerebriform connective tissue nevus in mosaic overgrowth syndromes.
Keppler-Noreuil KM; Burton-Akright J; Lindhurst MJ; Shwetar J; Sapp JC; Darling T; Biesecker LG
Cold Spring Harb Mol Case Stud; 2019 Aug; 5(4):. PubMed ID: 31371346
[TBL] [Abstract][Full Text] [Related]
39. Multiple meningiomas, craniofacial hyperostosis and retinal abnormalities in Proteus syndrome.
Gilbert-Barness E; Cohen MM; Opitz JM
Am J Med Genet; 2000 Jul; 93(3):234-40. PubMed ID: 10925389
[TBL] [Abstract][Full Text] [Related]
40. Low-level mesodermal somatic mutation mosaicism: late-onset craniofacial and cervical spinal hyperostoses.
Kubota Y; Mitsukawa N; Uchida M; Uchida Y; Akita S; Hasegawa M; Satoh K
Am J Med Genet A; 2014 Mar; 164A(3):741-7. PubMed ID: 24357582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
